Good morning, everyone, and how are you today? We are doing all right, under the circumstances, but as the saying goes, we are taking one day at a time. We are, after all, looking at months of challenges, but as the Morning Mayor used to say: Every day should be unwrapped like a precious gift. So while you tug on the ribbon, please join us for a delicious cup of stimulation. For those tracking this sort of thing, we have reached for maple bourbon this morning. Meanwhile, here are some tidbits to get you started. Stay safe.
A study of mild to moderate Covid-19 patients in China who were given remdesivir, the Gilead Sciences (GILD) experimental drug, was suspended, according to analysts at RBC Capital Markets, citing updated information on ClinicalTrials.gov. The reason cited was poor enrollment. This comes after a study in severe patients was recently ended for similar reasons. The mild-moderate study had planned to enroll 308 patients from Wuhan, China.
About the Author Reprints
